Here, we have demonstrated that therapeutically combining PM with Ad5-TRP2 resulted in inhibition of tumor growth and increased survival in melanoma-challenged mice, which was, in part, due to greatly increased systemic CD8+ T cell responses and to the enhanced accumulation of CD8+ T cells to the tumor and tumor periphery. This evidence concerns the gene CD8A and melanoma.